Nourianz Approved to Treat Off Episodes of Parkinson’s Disease

August 28, 2019 – The U.S. FDA has approved NourianzTM (istradefylline), manufactured by Kiowa Kirin, for use as an adjunctive treatment for adults who are also taking levodopa/carbidopa, have Parkinson's disease, and are experiencing off episodes.

Over time, standard medications for Parkinson's disease can begin to lose their effectiveness in individual patients. This leads to off episodes, in which the patient experiences a return or worsening of symptoms before their next dose of medication is due. Prescription drugs approved to treat patients who experience these episodes can help to bridge the gap between the time the primary medication therapy wears off, and the time the next dose of that therapy is due.

Nourianz, an adenosine A2A receptor antagonist, offers a novel compound for the treatment of off episodes. In clinical studies, patients treated with the drug experienced a statistically significant decrease from baseline in daily off time compared to those who received a placebo. Recommended dosing is 20mg per day, but can be increased to 40mg per day if needed. The product will be available in 20mg and 40mg tablets. Kiowa Kirin has not yet announced launch or pricing plans.